GHB Detection Beyond the Laboratory: Why Quantitative Saliva Analysis Matters

GHB detection is one of the most difficult challenges in modern drug testing.
Gamma-hydroxybutyrate, commonly known as GHB, is a small molecule with a short detection window, complex interpretation, and serious implications for public safety, emergency medicine, roadside testing, and forensic investigations.

The challenge is not only detecting GHB. The real challenge is interpreting it correctly — fast enough for the result to still matter.
Unlike many drugs of abuse, GHB is naturally present in the human body at low concentrations. This means that a simple “positive” result is not enough. Professionals need to understand how much GHB is present, whether the measured concentration may indicate exposure, and whether the result can support further medical, safety, or investigative decisions.
That is why quantitative GHB detection matters.

Why is GHB difficult to detect?

GHB is analytically challenging for several reasons.
It is a very small molecule. It is highly polar. It is naturally present in biological samples. It can also disappear quickly from the body after intake. Together, these factors make GHB very different from many other substances commonly included in drug testing panels.

In practical terms, this means that testing for GHB is not only a question of sensitivity. It is also a question of timing, sample type, concentration, and interpretation.
A result that arrives too late may be less useful.
A result that only says “detected” may be incomplete.
A result without concentration may be difficult to interpret.

For professionals working in emergency departments, roadside testing, clinical toxicology, or forensic investigations, this creates a major problem: decisions often need to be made quickly, but the most reliable analytical infrastructure is usually located in a central laboratory.

Why “GHB detected” is not enough

One of the most important facts about GHB is that it occurs naturally in the body.
Low concentrations of endogenous GHB can be found in blood, urine, and saliva, even in people who have not consumed the drug. SafePAS research demonstrated endogenous GHB concentrations in saliva between 0.15 and 3.33 mg/L.
This changes how GHB testing must be understood.
For many other drugs, the presence of the substance itself may already be highly meaningful. With GHB, the question is more complex. Because low levels can occur naturally, the result must help professionals understand whether the measured concentration is consistent with normal background levels or whether it may support suspected exposure.
In other words, GHB detection needs quantification.

As Jekaterina Mazina, CEO of SafePAS, explains:

“GHB is not a substance where a simple yes-or-no answer is enough. Because GHB is naturally present in the body and disappears quickly after intake, the key question is not only whether it is detected, but whether the measured concentration supports meaningful interpretation.”

That is the core reason why quantitative GHB analysis is so important.

Why does timing matter in GHB detection?

Timing matters because GHB is rapidly metabolised and eliminated from the body.
Detectable concentrations in biological samples can decline significantly within only a few hours after intake. This creates a narrow window where sample collection and analysis are most useful.
Every delay can matter.

In suspected GHB intoxication, suspected drug-facilitated crime, overdose investigation, or impaired-driving assessment, waiting hours or days for laboratory results may mean that important information is no longer available in the same way.

This does not mean that laboratory confirmation is not important. It is. But in time-sensitive cases, professionals may also need earlier analytical information to support immediate decisions.

That information may help answer questions such as:
– Was GHB present in the sample?
– What concentration was measured?
– Is the result above expected endogenous levels?
– Should the case be prioritised for confirmatory testing?
– Does the result support medical, safety, or investigative follow-up?

The shorter the detection window, the more important early analysis becomes.

Why saliva is a useful sample for GHB testing

Saliva, or oral fluid, is increasingly important in drug testing because it is practical in real-world conditions.
It is non-invasive.
It is easier to collect than blood.
It is difficult to adulterate.
It can be collected closer to the point of need.
It is already used in many roadside drug-screening workflows.

For GHB, saliva is especially interesting because it can support earlier sample collection in situations where time matters. Instead of waiting for a blood draw or sample transport to a distant laboratory, oral-fluid testing can bring analysis closer to the professional who needs the information.
But saliva also introduces analytical challenges.

Because GHB can occur naturally in saliva, a useful test must be able to measure concentration, not only detect presence. It must also account for matrix effects and naturally occurring background levels. This is why the analytical method matters.

SafePAS research demonstrated that GHB can be quantitatively measured in saliva using capillary electrophoresis. This scientific work forms part of the foundation behind the SafePAS approach to portable quantitative drug analysis.

What are the limits of traditional laboratory workflows?

Centralized laboratory methods remain essential in forensic toxicology and clinical analysis.
Methods such as GC-MS, LC-MS/MS, GC-FID, and capillary electrophoresis can provide strong analytical performance. They are important for confirmation, detailed interpretation, and formal reporting.

But they also require specialised laboratories, trained analytical staff, expensive instrumentation, sample transport, and time.
In many GHB-related situations, time is exactly what professionals do not have.
An emergency physician may be treating an unconscious patient.
A police officer may be investigating suspected impaired driving.
A forensic investigator may need to preserve evidence before the detection window closes.
A laboratory may need to prioritise urgent samples from a larger queue.

In these cases, the question is not whether laboratory methods are useful. They are. The question is whether professionals can access useful quantitative information earlier, before the opportunity for interpretation becomes weaker.
Portable quantitative analysis can help close that gap.

How can portable quantitative GHB analysis help?

Portable quantitative analysis is not designed to replace confirmatory laboratory methods. It is designed to complement them.
The value is earlier information.
If trained professionals can obtain a quantitative oral-fluid result closer to the time of concern, that result can support better decision-making before the case reaches the next stage.

For emergency medicine, earlier analytical information may help clinicians assess possible GHB exposure, communicate with toxicologists, and decide whether confirmatory laboratory testing is needed.

For law enforcement, it may help prioritise investigations, support roadside decision-making, and preserve relevant evidence during a short detection window.

For forensic laboratories, portable screening could help identify urgent samples, reduce unnecessary workload, and improve workflow efficiency before confirmatory analysis.

For public safety teams, it can support faster and better-informed decisions when uncertainty is high.
The key idea is simple:
GHB detection should not depend only on access to a distant specialized laboratory when decisions need to be made quickly.

Where does Drug Hunter fit?

Drug Hunter is a portable oral-fluid drug analyzer developed by SafePAS.
It is designed to identify selected substances and provide quantitative, substance-level results on site. The system uses capillary electrophoresis with native fluorescence detection and is built for professional use in settings where faster analytical information can support better decisions.
For GHB, the value is especially clear.

Because GHB is naturally present in the body, the result needs concentration. Because GHB disappears quickly, the result needs speed. Because GHB cases can involve emergency medicine, public safety, and forensic investigation, the workflow needs to support professional decision-making rather than simple yes/no screening.
Drug Hunter helps bring quantitative oral-fluid analysis closer to the point of need.

It does not remove the role of laboratory confirmation. It does not replace medical judgement. It does not make legal decisions by itself. Instead, it gives trained professionals earlier analytical information that can help them decide what should happen next.

Why does this matter for Europe?

Across Europe, professionals in healthcare, law enforcement, forensic science, and public safety face the same basic challenge: how to respond to suspected GHB exposure before the evidence disappears.

GHB may be involved in drug-impaired driving, recreational use, accidental overdose, suspected drug-facilitated crime, and organized drug trafficking. These are different contexts, but they share one operational problem.
The window for useful detection can be short.

When analysis is delayed, important information may be lost. When testing is only qualitative, interpretation may remain incomplete. When all analysis depends on central laboratories, professionals working at the point of need may have to act with limited information.
Portable quantitative analysis can make the response more practical.

What should professionals take from this?

GHB is not a simple substance to test for.
It is naturally present in the body.
It can disappear quickly after intake.
It requires quantitative interpretation.
It can be difficult to analyse with conventional workflows.
It often appears in situations where decisions must be made quickly.

This is why GHB detection needs to move beyond a simple “positive or negative” model.
The future of GHB testing is not only about detecting the molecule. It is about giving professionals the information they need early enough to act: what was measured, at what concentration, and whether the result supports further action.

Drug Hunter was developed for this kind of challenge — bringing portable, quantitative oral-fluid analysis closer to the professionals who need clearer information when time matters.

FAQ

Talk to SafePAS about GHB detection

SafePAS develops portable analytical technologies for quantitative detection of drugs and other small molecules.
If your organisation works in law enforcement, forensic science, emergency medicine, clinical toxicology, or public safety, contact SafePAS to discuss Drug Hunter, GHB detection, and portable oral-fluid analysis.